サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1718947

HIV治療薬の世界市場の評価：薬剤クラス別、主要ブランド別、流通チャネル別、地域別、機会、予測（2018年～2032年）

HIV Drugs Market Assessment, By Drug Class, By Major Brands, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 230 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
HIV治療薬の世界市場の評価：薬剤クラス別、主要ブランド別、流通チャネル別、地域別、機会、予測（2018年～2032年）
出版日: 2025年05月05日
発行: Market Xcel - Markets and Data
ページ情報: 英文 230 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のHIV治療薬の市場規模は、2024年の358億3,000万米ドルから2032年に498億3,000万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで4.21%の成長が見込まれす。HIV/AIDSの有病率の増加、HIV/AIDSに対する認識を高めるための各国政府の取り組みの活発化、利用可能なさまざまな治療ソリューションに対する認識の高まりは、市場成長の主な促進要因の一部です。世界保健機関（WHO）は、2023年末までに全世界で約3,990万人がHIVに感染していると推定しており、そのうち3,860万人が15歳以上、140万人が14歳以下です。

HIVの薬物療法には、ウイルス量を減らし、免疫機能を高め、HIV感染を予防するように設計された、幅広い抗レトロウイルス薬が含まれます。これらの薬剤は、HIV陽性者の寿命を延ばし、症状を管理し日和見感染のリスクを最小化することで、よりよい生活の質を確保するのに不可欠です。

当レポートでは、世界のHIV治療薬市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界のHIV治療薬市場の見通し（2018年～2032年）

  • 市場規模分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 薬剤クラス別
      • インテグラーゼ阻害薬
      • 非ヌクレオシド系逆転写酵素阻害薬（NRTI）
      • 併用HIV薬
      • その他
    • 主要ブランド別
      • Biktarvy
      • Dovato
      • Genvoya
      • Descovy
      • Triumeq
      • Prezista
      • Tivicay
      • Odefsey
      • その他
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2024年）
  • 市場マップ分析（2024年）
    • 薬剤クラス別
    • 主要ブランド別
    • 流通チャネル別
    • 地域別

第6章 北米のHIV治療薬市場の見通し（2018年～2032年）

  • 市場規模分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 薬剤クラス別
      • インテグラーゼ阻害薬
      • 非ヌクレオシド系逆転写酵素阻害薬（NRTI）
      • 併用HIV薬
      • その他
    • 主要ブランド別
      • Biktarvy
      • Dovato
      • Genvoya
      • Descovy
      • Triumeq
      • Prezista
      • Tivicay
      • Odefsey
      • その他
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • シェア：国別
      • 米国
      • カナダ
      • メキシコ
  • 各国の市場の評価
    • 米国のHIV薬市場の見通し（2018年～2032年）
      • 市場規模分析と予測
      • 市場シェアの分析と予測
    • カナダ
    • メキシコ

第7章 欧州のHIV薬市場の見通し（2018年～2032年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋のHIV治療薬市場の見通し（2018年～2032年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米のHIV治療薬市場の見通し（2018年～2032年）

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカのHIV治療薬市場の見通し（2018年～2032年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

  • 規制当局の承認
  • 臨床試験

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 4. Global HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global HIV Drugs Market Share (%), By Region, 2018-2032F
  • Figure 6. North America HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 8. North America HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 9. North America HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America HIV Drugs Market Share (%), By Country, 2018-2032F
  • Figure 11. United States HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 13. United States HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 14. United States HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. Canada HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 18. Canada HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 21. Mexico HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 22. Mexico HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Europe HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 26. Europe HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe HIV Drugs Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 30. Germany HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 31. Germany HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 34. France HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 35. France HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 38. Italy HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 39. Italy HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 42. United Kingdom HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 43. United Kingdom HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 46. Russia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 47. Russia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. Netherlands HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 51. Netherlands HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 54. Spain HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 55. Spain HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 58. Turkey HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 59. Turkey HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. Poland HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 63. Poland HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. South America HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. South America HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 66. South America HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 67. South America HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. South America HIV Drugs Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Brazil HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 71. Brazil HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 72. Brazil HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. Argentina HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. Argentina HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 75. Argentina HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 76. Argentina HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Asia-Pacific HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Asia-Pacific HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 79. Asia-Pacific HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 80. Asia-Pacific HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Asia-Pacific HIV Drugs Market Share (%), By Country, 2018-2032F
  • Figure 82. India HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 83. India HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 84. India HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 85. India HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 86. China HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 87. China HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 88. China HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 89. China HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Japan HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Japan HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 92. Japan HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 93. Japan HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. Australia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. Australia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 96. Australia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 97. Australia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 98. Vietnam HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 99. Vietnam HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 100. Vietnam HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 101. Vietnam HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 102. South Korea HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 103. South Korea HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 104. South Korea HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 105. South Korea HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. Indonesia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Indonesia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 108. Indonesia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 109. Indonesia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Philippines HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Philippines HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 112. Philippines HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 113. Philippines HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 116. Middle East & Africa HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 117. Middle East & Africa HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa HIV Drugs Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 121. Saudi Arabia HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 122. Saudi Arabia HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 125. UAE HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 126. UAE HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa HIV Drugs Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa HIV Drugs Market Share (%), By Drug Class, 2018-2032F
  • Figure 129. South Africa HIV Drugs Market Share (%), By Major Brands, 2018-2032F
  • Figure 130. South Africa HIV Drugs Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Major Brands Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13072

Global HIV drugs market is projected to witness a CAGR of 4.21% during the forecast period 2025-2032, growing from USD 35.83 billion in 2024 to USD 49.83 billion in 2032. Increasing prevalence of HIV/AIDS, rising efforts of different governments to increase awareness about the condition, and growing awareness about the various treatment solutions available are some of the major factors driving the growth of the market. The World Health Organization estimates that approximately 39.9 million people across the globe were living with HIV by the end of 2023 of which 38.6 million were above the age of 15, while 1.4 million were 14 and younger.

HIV drug therapies include a wide array of antiretroviral medications designed to reduce viral load, boost immune function, and prevent HIV transmission. These drugs are critical for prolonging the life expectancy for HIV-positive individuals and in ensuring a better quality of life by managing symptoms and minimizing the risk of opportunistic infections.

Supportive Regulatory Initiatives Boost Market Growth

Supportive government policies and regulatory initiatives such as priority review incentivize leading market players and pharmaceutical companies to focus on product innovation and introduction of new technologies. Regulatory agencies such as the FDA and EMA are expediting drug approvals, particularly for innovative therapies such as long-acting injectables and fixed-dose combinations, ensuring that patients benefit from the latest advancements. For instance, in February 2025, Gilead Sciences, Inc. received approval from the US FDA for its New Drug Application (NDA) submission for lenacapavir, its injectable HIV-1 capsid inhibitor, indicated for the prevention of HIV as pre-exposure prophylaxis (PrEP). Furthermore, these agencies also facilitate the introduction of generics following the expiration of the patents, which increases competition, increases the affordability of the drugs, and improves their accessibility. Additionally, public health campaigns, early diagnosis initiatives, and insurance coverage reforms are raising awareness and reducing stigma about HIV infections, further driving the market's growth and expansion.

Strategic Partnerships and Collaborations Support Market Expansion

The key players of the market are heavily investing in research and development activities to develop safer and more effective treatments for HIV, targeting drug resistance and focusing on reducing long-term side effects. The shift toward long-acting formulations, including cabotegravir and rilpivirine injectables, exemplifies innovation aimed at improving adherence.

Moreover, strategic collaborations between public and private entities are streamlining drug approval and distribution processes and ensuring the affordability and accessibility of the medications. For instance, in October 2024, Gilead Sciences, Inc. signed a royalty-free and non-exclusive voluntary licensing agreement with six leading pharmaceutical manufacturers to sell and manufacture generic lenacapavir. The agreement also covers HIV treatment in adults with multi-drug-resistant HIV.

Additionally, in Africa and Asia, local production is increasingly supported by international partnerships, strengthening regional resilience and improving treatment access. Furthermore, digital health platforms and mobile clinics are being leveraged to extend patient monitoring and medication adherence support in remote areas. These technology-driven interventions are enhancing treatment efficacy and facilitating real-time health data collection, contributing to improved patient outcomes and rapid market growth.

Hospitals Pharmacies Account for Significant Share of the Market

The segment's dominance can be attributed to the central role played by hospitals in comprehensive treatment and management of HIV/AIDS. Hospital pharmacies provide counselling, close monitoring of the condition, and specialized medication management, which are essential for minimizing drug interactions, adjusting regimens, and optimizing adherence for complex cases. Additionally, the direct collaboration between hospital pharmacies and healthcare providers further allows for integrated care and provision of tailored therapy solutions, improving treatment outcomes.

Furthermore, leading hospital pharmacies across the globe are focusing on expanding their market presence, further contributing to the segment's growth. For instance, in March 2025, Apollo HealthCo Ltd, operator of Apollo Pharmacy and online platform Apollo 24/7, announced expansion of its offline pharmacy network in Bengal, India.

North America Holds Major Market Share

North America is expected to hold a significant share of the market in the coming years owing to the rising prevalence of HIV infections, increasing awareness among the general population, and the strong presence of leading pharmaceutical companies in the region. Additionally, the presence of robust healthcare systems in the regions ensures broad access to cutting-edge medications and healthcare technologies, while government initiatives such as the Ryan White HIV/AIDS Program and the Ending the HIV Epidemic plan subsidize treatment costs, improve the accessibility of HIV drugs, especially for vulnerable populations.

Meanwhile, the Asia-Pacific is expected to witness rapid growth over the forecast period owing to rapid population expansion, increasing efforts of leading pharmaceutical companies to bolster the availability of advanced therapeutic solutions in the region, and growing awareness among the population. Leading organizations are also joining forces to combat the growing threat of HIV infection in the region, providing lucrative growth opportunities for the market. For instance, in April 2025, the UNICEF, UNAIDS, and WHO launched the Regional Roadmap for the Triple Elimination of Mother-to-Child Transmission (EMTCT) of Syphilis, HIV, and Hepatitis B in the Asia-Pacific Region (2024-2030).

Impact of the U.S. Tariff on Global HIV Drugs Market

The recently introduced tariffs are expected to disrupt supply chains and impact the availability of antiretroviral therapies and reduce their affordability. Indian generic drug manufacturers are also expected to observe financial strains because of the tariffs as these manufacturers operate on thin margins, potentially forcing them to withdraw from the market in the United States. Additionally, various manufacturers across the globe might need to restructure their operations and move their manufacturing units to avoid tariffs, resulting in potential delays in drug availability. Such delays are particularly detrimental for HIV positive patients as medication adherence is crucial for managing the condition.

Key Players Landscape and Outlook

The key players of the market are focusing on receiving approvals from different regulatory and governing bodies across the globe to market and distribute their HIV drugs. For instance, in February 2023 ViiV Healthcare, a subsidiary of GlaxoSmithKline plc, received marketing authorization for Triumeq from the European Commission. By providing child-friendly dispersible tablets and lowering the minimum weight for Triumeq's administration, ViiV is aiding healthcare professionals in improving viral suppression rates and treatment adherence among younger patients. Such approvals support innovations and inclusivity in HIV therapy, encouraging leading market players and pharmaceutical companies to develop pediatric formulations, ensuring that the underserved patient population is provided with viable treatment solutions, providing lucrative growth opportunities for the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global HIV Drugs Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Integrase Inhibitors
      • 5.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • 5.2.1.3. Combination HIV Medicines
      • 5.2.1.4. Other
    • 5.2.2. By Major Brands
      • 5.2.2.1. Biktarvy
      • 5.2.2.2. Dovato
      • 5.2.2.3. Genvoya
      • 5.2.2.4. Descovy
      • 5.2.2.5. Triumeq
      • 5.2.2.6. Prezista
      • 5.2.2.7. Tivicay
      • 5.2.2.8. Odefsey
      • 5.2.2.9. Others
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Drug Class
    • 5.3.2. By Major Brands
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America HIV Drugs Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Drug Class
      • 6.2.1.1. Integrase Inhibitors
      • 6.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      • 6.2.1.3. Combination HIV Medicines
      • 6.2.1.4. Other
    • 6.2.2. By Major Brands
      • 6.2.2.1. Biktarvy
      • 6.2.2.2. Dovato
      • 6.2.2.3. Genvoya
      • 6.2.2.4. Descovy
      • 6.2.2.5. Triumeq
      • 6.2.2.6. Prezista
      • 6.2.2.7. Tivicay
      • 6.2.2.8. Odefsey
      • 6.2.2.9. Others
    • 6.2.3. By Distribution Channel
      • 6.2.3.1. Hospital Pharmacies
      • 6.2.3.2. Retail Pharmacies
      • 6.2.3.3. Online Pharmacies
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States HIV Drugs Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Drug Class
          • 6.3.1.2.1.1. Integrase Inhibitors
          • 6.3.1.2.1.2. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
          • 6.3.1.2.1.3. Combination HIV Medicines
          • 6.3.1.2.1.4. Other
        • 6.3.1.2.2. By Major Brands
          • 6.3.1.2.2.1. Biktarvy
          • 6.3.1.2.2.2. Dovato
          • 6.3.1.2.2.3. Genvoya
          • 6.3.1.2.2.4. Descovy
          • 6.3.1.2.2.5. Triumeq
          • 6.3.1.2.2.6. Prezista
          • 6.3.1.2.2.7. Tivicay
          • 6.3.1.2.2.8. Odefsey
          • 6.3.1.2.2.9. Others
        • 6.3.1.2.3. By Distribution Channel
          • 6.3.1.2.3.1. Hospital Pharmacies
          • 6.3.1.2.3.2. Retail Pharmacies
          • 6.3.1.2.3.3. Online Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe HIV Drugs Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific HIV Drugs Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America HIV Drugs Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa HIV Drugs Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Regulatory Approvals
  • 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Gilead Sciences, Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. GlaxoSmithKline plc
    • 21.3.3. Bristol-Myers Squibb Company
    • 21.3.4. Johnson & Johnson Services, Inc.
    • 21.3.5. Teva Pharmaceutical Industries Ltd.
    • 21.3.6. Cipla Ltd.
    • 21.3.7. AbbVie Inc.
    • 21.3.8. Boehringer Ingelheim International GmbH
    • 21.3.9. Merck & Co., Inc.
    • 21.3.10. F. Hoffmann-La Roche Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer